Breckenridge Pharmaceutical Inc, a US subsidiary of Japan-based Towa Pharmaceutical, announced on Friday that it has signed a multi-product agreement with Germany-based Welding GmbH & Co.
According to the contract, Welding GmbH & Co will develop, manufacture and provide pharmaceutical products for marketing, sale and distribution by the company.
Tthe contact currently covers one delayed release tablet product and two injectable products. Breckenridge has submitted one ANDA to the United States Food and Drug Administration (FDA), one ANDA is likely to be submitted to the FDA this month and one ANDA is in an advanced stage of development.
According to industry sales data, the brand and generics of these three products had annual sales of USD300m during the twelve months ending April 2021.
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US